Practical solutions for hypertensive patients with dyslipidemia☆

Arterial hypertension and dyslipidemia often coexist and constitute major risk factors of ischemic heart disease.Aggressive treatment of both comorbidities is of paramount importance to decrease global risk.Low adherence is a determinant of poor risk factor control and increases adverse cardiovascular outcomes.Regarding treatment of hypertension, combination therapy is superior in achieving target BP values compared to up-titrating monotherapy and it is recommended in hypertension guidelines.The combined use of drugs in a single pill formulation increases adherence and reduces cardiovascular risk.Our review of the literature indicates that triple therapy with an angiotensin converting enzyme inhibitor, a calcium channel blocker and a statin is associated with a significant reduction in major cardiovascular events.This is attributed to synergy at the vascular, and is translated into efficacy at the clinical level.